SeaSpine Stock Is Trading Higher On FDA Approval For 7D Surgical Spine Module

by Vandana Singh, Benzinga Editor

July 8, 2021 6:44 AM | 1 min read |

The FDA has given 510(k) clearance to SeaSpine Holdings Corporation's SPNE 7D Percutaneous Spine Module for minimally invasive surgery.
This news follows SeaSpine's recent acquisition of 7D Surgical, a Toronto-based company that develops advanced optical technologies and machine vision-based registration algorithms for surgical navigation to improve patient care.
The Company is preparing a limited release of the Percutaneous Spine Module in Q3 of 2021.
The 7D FLASH Navigation System uses visible light to quickly create a three-dimensional image for surgical navigation, resulting in shorter and more efficient spinal procedures.
Price Action: SPNE shares are up 12.9% at $21.27 during the premarket session on the last check Thursday.

Posted In: Long Ideas News Health Care Small Cap FDA Movers Trading Ideas General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.